OTC薬市場- 世界の産業規模、シェア、動向、機会、予測、製品別、剤形別、地域別セグメント、競合、2020年～2030年

OTC薬の世界市場は、2024年に102億5,000万米ドルと評価され、2030年には154億8,000万米ドルに達すると予測され、予測期間中のCAGRは7.31%です。

OTC薬は、処方箋を必要とせず、頭痛、アレルギー、風邪、消化器系の問題、軽い皮膚の炎症など、一般的な健康状態を管理するための便利で費用対効果の高い選択肢です。ヘルスケアコストの増加とセルフケア志向の高まりが、市場成長の主な要因となっています。消費者は、専門家による診察の必要性を減らす、利用しやすい代替治療法を求めており、製薬会社はOTCポートフォリオを拡大し、革新的なデリバリー形態や消費者啓蒙活動への投資を促しています。しかし、特に薬剤師の監督や規制強化が限定的な地域では、過剰使用のリスクやセルフメディケーションによる合併症の可能性など、不適切な使用に関する課題によって市場の拡大は抑制されています。

市場促進要因

ヘルスケア産業の成長

主な市場課題

誤用とセルフメディケーションのリスク

主要市場動向

ニッチOTCセグメントの成長

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19別世界のOTC薬市場への影響

第5章 世界のOTC薬市場の見通し

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 製品別（咳止め、風邪薬、ビタミン、ミネラル、サプリメント（VMS）、鎮痛剤、胃腸薬、皮膚科薬、その他）
  • 剤形別（錠剤、カプセル剤、液剤、クリーム／ローション／軟膏、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のOTC薬市場の見通し

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のOTC薬市場の見通し

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のOTC薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のOTC薬市場の見通し

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東およびアフリカのOTC薬市場の見通し

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界のOTC薬市場： SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

The Global Over the Counter (OTC) Drugs Market was valued at USD 10.25 Billion in 2024 and is projected to reach USD 15.48 Billion by 2030, registering a CAGR of 7.31% during the forecast period. OTC drugs are a convenient and cost-effective option for managing common health conditions such as headaches, allergies, colds, digestive issues, and minor skin irritations without requiring a prescription. Increasing healthcare costs and a growing inclination toward self-care are major contributors to market growth. Consumers are seeking accessible treatment alternatives that reduce the need for professional consultations, prompting pharmaceutical companies to expand their OTC portfolios and invest in innovative delivery forms and consumer awareness initiatives. However, the market's expansion is tempered by challenges related to improper use, including risks of overuse and potential complications due to self-medication, particularly in regions with limited pharmacist oversight or regulatory enforcement.

Key Market Drivers

Growth in Healthcare Industry

The growing global healthcare industry significantly supports the expansion of the OTC drugs market. Generating over USD 4 trillion annually, the healthcare sector includes highly profitable domains such as pharmaceuticals and biotechnology, which contribute nearly USD 850 billion, and medical technology and diagnostics, accounting for more than USD 400 billion. As healthcare systems become more focused on patient-centered care and cost efficiency, consumers are increasingly turning to OTC medications to manage routine health issues independently. This shift reflects a broader movement toward preventative care, convenience, and greater consumer empowerment, which is driving demand for safe, effective, and readily available OTC treatment options.

Key Market Challenges

Risk of Misuse and Self-Medication

A major concern in the OTC drugs market is the potential for misuse and self-medication. The ease of access to OTC products, while beneficial for minor ailments, can result in unintended health risks when these products are used without adequate medical guidance. Improper dosing, extended use beyond recommended guidelines, or reliance on OTC drugs to manage symptoms of more serious conditions can lead to adverse outcomes. Misuse is particularly common with medications such as analgesics, antacids, and antihistamines, which consumers may not fully understand in terms of contraindications or possible drug interactions. This lack of oversight increases the risk of masking underlying illnesses or exacerbating health issues due to incorrect use.

Key Market Trends

Growth of Niche OTC Segments

The market is witnessing rising interest in niche OTC segments tailored to specific consumer needs and health conditions. As awareness of individual health concerns grows, consumers are seeking more targeted non-prescription solutions that go beyond general-purpose remedies. Categories such as sleep aids, digestive health supplements, women's health products, pediatric treatments, and plant-based options are gaining momentum. These offerings respond to a rising preference for self-managed wellness and preventive care. For instance, sleep aids typically rely on antihistamines like diphenhydramine and doxylamine to reduce wakefulness. Growing attention to conditions such as insomnia, digestive discomfort, and seasonal allergies has fueled demand for customized OTC solutions, encouraging companies to diversify their offerings and explore functional innovations aligned with consumer wellness trends.

Key Market Players

• Sanofi SA
• Pfizer Inc.
• GlaxoSmithKline plc
• Perrigo Company plc
• Reckitt Benckiser Group PLC
• Takeda Pharmaceutical Company Ltd
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Ltd.
• Teva Pharmaceutical Industries Ltd.
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global Over the Counter (OTC) Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Over the Counter (OTC) Drugs Market, By Product:

• Cough
• Cold & Flu
• Vitamins, Mineral, & Supplements (VMS)
• Analgesics
• Gastrointestinal Products
• Dermatology Products
• Others

Over the Counter (OTC) Drugs Market, By Dosage Form:

• Tablets
• Capsules
• Liquids & Solutions
• Cream/Lotion/Ointments
• Others

Over the Counter (OTC) Drugs Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Over the Counter (OTC) Drugs Market.

Available Customizations

Global Over the Counter (OTC) Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Over the Counter (OTC) Drugs Market

5. Global Over the Counter (OTC) Drugs Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Cough, Cold & Flu, Vitamins, Mineral, & Supplements (VMS), Analgesics, Gastrointestinal Products, Dermatology Products, Others)
  • 5.2.2. By Dosage Form (Tablets, Capsules, Liquids & Solutions, Cream/Lotion/Ointments, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Over the Counter (OTC) Drugs Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Dosage Form
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Over the Counter (OTC) Drugs Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Dosage Form
  • 6.3.2. Mexico Over the Counter (OTC) Drugs Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Dosage Form
  • 6.3.3. Canada Over the Counter (OTC) Drugs Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Dosage Form

7. Europe Over the Counter (OTC) Drugs Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Dosage Form
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Over the Counter (OTC) Drugs Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Dosage Form
  • 7.3.2. Germany Over the Counter (OTC) Drugs Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Dosage Form
  • 7.3.3. United Kingdom Over the Counter (OTC) Drugs Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Dosage Form
  • 7.3.4. Italy Over the Counter (OTC) Drugs Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Dosage Form
  • 7.3.5. Spain Over the Counter (OTC) Drugs Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Dosage Form

8. Asia Pacific Over the Counter (OTC) Drugs Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Dosage Form
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Over the Counter (OTC) Drugs Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Dosage Form
  • 8.3.2. India Over the Counter (OTC) Drugs Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Dosage Form
  • 8.3.3. South Korea Over the Counter (OTC) Drugs Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Dosage Form
  • 8.3.4. Japan Over the Counter (OTC) Drugs Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Dosage Form
  • 8.3.5. Australia Over the Counter (OTC) Drugs Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Dosage Form

9. South America Over the Counter (OTC) Drugs Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Dosage Form
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Over the Counter (OTC) Drugs Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Dosage Form
  • 9.3.2. Argentina Over the Counter (OTC) Drugs Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Dosage Form
  • 9.3.3. Colombia Over the Counter (OTC) Drugs Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Dosage Form

10. Middle East and Africa Over the Counter (OTC) Drugs Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Dosage Form
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Over the Counter (OTC) Drugs Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Dosage Form
  • 10.3.2. Saudi Arabia Over the Counter (OTC) Drugs Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Dosage Form
  • 10.3.3. UAE Over the Counter (OTC) Drugs Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Dosage Form

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions : Conflicts, Pandemics and Trade Barriers

14. Global Over the Counter (OTC) Drugs Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Sanofi SA
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. Pfizer Inc.
• 16.3. GlaxoSmithKline plc
• 16.4. Perrigo Company plc
• 16.5. Reckitt Benckiser Group PLC
• 16.6. Takeda Pharmaceutical Company Ltd
• 16.7. Boehringer Ingelheim International GmbH
• 16.8. Sun Pharmaceutical Industries Ltd.
• 16.9. Teva Pharmaceutical Industries Ltd.
• 16.10. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer